ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer

[1]  Daniel Birnbaum,et al.  Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization , 2014, Molecular Cancer.

[2]  A. Zolkiewska,et al.  Phenotypic Diversity of Breast Cancer-Related Mutations in Metalloproteinase-Disintegrin ADAM12 , 2014, PloS one.

[3]  A. Børresen-Dale,et al.  Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c , 2014, British Journal of Cancer.

[4]  M. McBride,et al.  Canonical Transforming Growth Factor-b Signaling Regulates Disintegrin Metalloprotease Expression in Experimental Renal Fibrosis via miR-29 , 2022 .

[5]  E. Howe,et al.  MicroRNA regulation of epithelial plasticity in cancer. , 2013, Cancer letters.

[6]  A. Zolkiewska,et al.  Alternative mRNA Splicing Generates Two Distinct ADAM12 Prodomain Variants , 2013, PloS one.

[7]  S. Mallik,et al.  A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. , 2013, Biochimica et biophysica acta.

[8]  C. Fan,et al.  Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis , 2013, Clinical & Experimental Metastasis.

[9]  M. Pichler,et al.  The Role of MicroRNAs in Breast Cancer Stem Cells , 2013, International journal of molecular sciences.

[10]  A. Zolkiewska,et al.  Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype , 2013, Breast Cancer Research and Treatment.

[11]  B. Jacobsen,et al.  Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4 , 2013, Oncogene.

[12]  Z. Werb,et al.  GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression , 2013, Nature Cell Biology.

[13]  Charles M. Perou,et al.  Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes , 2011, Breast Cancer Research and Treatment.

[14]  J. Foekens,et al.  miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs , 2013, Breast Cancer Research.

[15]  Zdenko Herceg,et al.  MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells , 2013, BMC Genomics.

[16]  A. Zolkiewska,et al.  An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[17]  Dorte Stautz,et al.  Functional Analysis of a Breast Cancer-Associated Mutation in the Intracellular Domain of the Metalloprotease ADAM12 , 2012, PloS one.

[18]  P. Kronqvist,et al.  ADAM12 Produced by Tumor Cells Rather than Stromal Cells Accelerates Breast Tumor Progression , 2011, Molecular Cancer Research.

[19]  Sophia Hsin-Jung Li,et al.  Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast , 2011, Cell.

[20]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[21]  Danqiong Sun,et al.  Metalloprotease-Disintegrin ADAM12 Expression Is Regulated by Notch Signaling via MicroRNA-29* , 2011, The Journal of Biological Chemistry.

[22]  Israel Steinfeld,et al.  miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors , 2011, PloS one.

[23]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[24]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[25]  F. Yu,et al.  Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells , 2010, Oncogene.

[26]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[27]  G. Goodall,et al.  microRNAs and EMT in Mammary Cells and Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.

[28]  Leming Shi,et al.  Effect of training-sample size and classification difficulty on the accuracy of genomic predictors , 2010, Breast Cancer Research.

[29]  D. Epstein,et al.  Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress , 2009, Molecular vision.

[30]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[31]  Michael F. Clarke,et al.  Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells , 2009, Cell.

[32]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[33]  U. Wewer,et al.  Targeting ADAM12 in human disease: head, body or tail? , 2009, Current pharmaceutical design.

[34]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[35]  Emilia Dyczynska,et al.  Breast cancer‐associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein , 2008, International journal of cancer.

[36]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[37]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[38]  J. Couchman,et al.  Cellular roles of ADAM12 in health and disease. , 2008, The international journal of biochemistry & cell biology.

[39]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[40]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[41]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[42]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[43]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[44]  P. Kronqvist,et al.  A role for ADAM12 in breast tumor progression and stromal cell apoptosis. , 2005, Cancer research.

[45]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[46]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.